The Europe Clinical Trial Supply & Logistics Market would witness market growth of 7.1% CAGR during the forecast period (2022-2028).
Pharmaceutical and biotechnology companies are investing more in R&D and expanding their facilities in preparation for the approval and release of new pharmaceuticals on the market. High R&D expenditures and robust supply and logistics infrastructure will likely boost the likelihood of successful treatment or medicine. For example, DHL Freight increased its network in Germany in July 2022 by purchasing a new facility in Mettmann, near Düsseldorf.
This endeavor was conducted following the recent opening of a new facility in Erlensee, near Frankfurt, Germany, and the acquisition of a site from the logistics company Leupold in Gochsheim, around Würzburg, Germany. The participants continually extend their facilities, collaborate, and engage in mergers, partnerships, and acquisitions.
These are essential strategic initiatives that are changing the dynamics of the industry. For instance, in June 2022, Catalent announced that it would extend its main packaging capabilities at its clinical supply facility in Japan, by constructing an elevated blister packaging line to complement its already automated bottling line.
This market is driven by the rapid growth in the number of cancer cases and the increased focus of researchers on the utilization of biologics for cancer treatment. In 2018, there were an estimated 3,9 million new cases of cancer and 1,9 million cancer-related deaths in Europe. Female breast cancer (523,000 new cases, 13% of all cancer cases), colorectum cancer (500,000 new cases, 13%), lung cancer (470,000 new cases, 12%), and prostate cancer (450,000 new cases, 12%) were the most prevalent cancers on the continent. Together they accounted for nearly half of the total cancer burden.
Biologic therapies utilize the immune system and the body's ability to fight cancer or heal healthy tissue following treatment, making them increasingly popular over conventional cancer treatment methods. Thus, the increased incidence of cancer is driving the expansion of biologics, which is anticipated to experience significant growth for the aforementioned reasons. Consequently, these factors fuel the expansion of the Clinical Trial Supply & Logistics Market in Europe.
The Germany market dominated the Europe Clinical Trial Supply & Logistics Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $348.7 Million by 2028.The UK market is anticipated to grow at a CAGR of 6.2% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 7.9% during (2022 - 2028).
Based on End-user, the market is segmented into Pharmaceuticals, Biologicals and Medical Device. Based on Therapeutic Area, the market is segmented into Cardiovascular Diseases, Respiratory Diseases, CNS & Mental Disorders, Oncology and Others. Based on Phase, the market is segmented into Phase III, Phase II, Phase I and Phase IV. Based on Service, the market is segmented into Logistics & Distribution, Comparator Sourcing, Storage & Retention, Packaging, Labeling, & Blinding, Manufacturing and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Clinical Trial Supply & Logistics Market will Hit $5.5 Billion by 2028, at a CAGR of 7.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc., Catalent, Inc., Marken (United Parcel Service of America, Inc.), Piramal Enterprises Limited, FedEx Corporation, Inizio Group Limited (Clayton, Dubilier & Rice), Parexel International Corporation (Phoenix Parentco, Inc.), Almac Group, Movianto (Walden Group SAS), and Deutsche Post DHL Group (The Deutsche Post AG)
By End-user
By Therapeutic Area
By Phase
By Service
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
